BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 17159191)

  • 1. Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing.
    Tercyak KP; Peshkin BN; Brogan BM; DeMarco T; Pennanen MF; Willey SC; Magnant CM; Rogers S; Isaacs C; Schwartz MD
    J Clin Oncol; 2007 Jan; 25(3):285-91. PubMed ID: 17159191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
    Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
    Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
    Hamilton JG; Genoff MC; Salerno M; Amoroso K; Boyar SR; Sheehan M; Fleischut MH; Siegel B; Arnold AG; Salo-Mullen EE; Hay JL; Offit K; Robson ME
    Breast Cancer Res Treat; 2017 Apr; 162(2):297-306. PubMed ID: 28150129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients.
    Tynan M; Peshkin BN; Isaacs C; Willey S; Valdimarsdottir HB; Nusbaum R; Hooker G; O'Neill SC; Jandorf L; Kelly SP; Heinzmann J; Kelleher S; Poggi E; Schwartz MD
    Breast Cancer Res Treat; 2020 Feb; 180(1):177-185. PubMed ID: 31894446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgical and financial implications of genetic counseling and requests for concurrent prophylactic mastectomy.
    Murphy RX; Adkinson JM; Namey T; Eid S; Bleznak A
    Ann Plast Surg; 2010 May; 64(5):684-7. PubMed ID: 20395792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
    Metcalfe KA; Eisen A; Poll A; Candib A; McCready D; Cil T; Wright F; Demsky R; Mancuso T; Sun P; Narod SA
    Ann Surg Oncol; 2021 Sep; 28(9):4967-4973. PubMed ID: 33761021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women's preferences for contralateral prophylactic mastectomy following unilateral breast cancer: What risk-reduction makes it worthwhile?
    Tesson S; Richards I; Porter D; Phillips KA; Rankin N; Costa D; Musiello T; Marven M; Butow P
    Breast; 2017 Feb; 31():233-240. PubMed ID: 27969575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic mastectomy for the prevention of breast cancer.
    Lostumbo L; Carbine N; Wallace J; Ezzo J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD002748. PubMed ID: 15495033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
    Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
    Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should the use of contralateral prophylactic mastectomy be increasing as it is?
    Wood WC
    Breast; 2009 Oct; 18 Suppl 3():S93-5. PubMed ID: 19914552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact.
    Wevers MR; Hahn DE; Verhoef S; Bolhaar MD; Ausems MG; Aaronson NK; Bleiker EM
    Patient Educ Couns; 2012 Oct; 89(1):89-95. PubMed ID: 22543000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Halbert CH; DeMarco T; Lawrence W; Main D; Finch C; Magnant C; Pennanen M; Tsangaris T; Willey S; Isaacs C
    J Clin Oncol; 2004 May; 22(10):1823-9. PubMed ID: 15067026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initial experience with surgical treatment planning in the newly diagnosed breast cancer patient at high risk for BRCA-1 or BRCA-2 mutation.
    Stolier AJ; Fuhrman GM; Mauterer L; Bolton JS; Superneau DW
    Breast J; 2004; 10(6):475-80. PubMed ID: 15569201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Satisfaction with prophylactic mastectomy and breast reconstruction in genetically predisposed women.
    Bresser PJ; Seynaeve C; Van Gool AR; Brekelmans CT; Meijers-Heijboer H; van Geel AN; Menke-Pluijmers MB; Duivenvoorden HJ; Klijn JG; Tibben A
    Plast Reconstr Surg; 2006 May; 117(6):1675-82; discussion 1683-4. PubMed ID: 16651934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study.
    Brandberg Y; Sandelin K; Erikson S; Jurell G; Liljegren A; Lindblom A; Lindén A; von Wachenfeldt A; Wickman M; Arver B
    J Clin Oncol; 2008 Aug; 26(24):3943-9. PubMed ID: 18711183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.